On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the treatments are largely overpriced and recommended steep discounts for at least three of the five therapies. There is ample reason to question ICER’s findings in this report.
Click here to read PAAP’s Last Word on Atopic Dermatitis.
Click here to read a deeper analysis from PAAP Advisor Dr. Paul Langley.